The Independent Product Group (“IPG”) is established to provide scientific advice on COVID-19 vaccines and make technical recommendations to the Office of the COVAX Facility on the inclusion of vaccines in the COVAX Facility, by regularly reviewing the COVAX Facility portfolio for balance and review updates on availability of vaccines and consider any implications for the COVAX Facility portfolio.

Drawing on COVAX’s unique experience enabling an unprecedented global rollout at scale during a pandemic, this paper outlines the key challenges the mechanism faced in seeking to ensure equitable access to COVID-19 vaccines, the actions it took in response and recommendations for the future.

Gavi is committed to creating a work environment that is safe and professional where employees work together in an atmosphere of mutual trust and where diversity and inclusion are valued. Gavi does not tolerate any form of discrimination or harassment towards and between its employees, which constitute misconduct and may result in investigations and the instigation of disciplinary measures up to and including the termination of an employment contract in accordance with Gavi’s Investigation and Disciplinary Procedures.